FDAapproval95% confidence
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Varenicline Tartrate; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Smoking Cessation · Nicotine Receptor Agonist
- Sub-indication
- General
Related signal: FDA Approves Varenicline Tartrate ANDA219382 by Somerset Therap LLC